Was ist die Webseite?

Prurigo Nodularis League

Startseite
Deutschland
Münster
Prurigo Nodularis League

Despite its prevalence and severity, prurigo nodularis remains a relatively unknown skin disease. Prurigo nodularis ist eine relativ unerforschte Erkrankung.

Our goal is to raise global awareness and provide current news relating to this debilitating illness. Hier finden Sie aktuelle News rund um das Netzwerk Prurigo nodularis Liga.

01/06/2026

🧬𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗶𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗼𝗿𝘆 𝘀𝘂𝗯𝘁𝘆𝗽𝗲𝘀 𝗶𝗻 𝗖𝗵𝗿𝗼𝗻𝗶𝗰 𝗣𝗿𝘂𝗿𝗶𝗴𝗼 𝘄𝗶𝘁𝗵 𝗮𝗻𝗱 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗮𝘁𝗼𝗽𝗶𝗰 𝗱𝗲𝗿𝗺𝗮𝘁𝗶𝘁𝗶𝘀

🔍 A recent study investigated differences between patients with chronic prurigo with and without atopic dermatitis.

The researchers found that both groups showed marked skin inflammation, impaired skin barrier function, and changes in genes linked to nerve function and skin repair. These findings support the idea that chronic prurigo develops through complex interactions between the immune system, skin cells, and sensory nerves.

However, patients who also had atopic dermatitis showed stronger inflammatory activity🔥.

💉 𝗪𝗵𝘆 𝗶𝘀 𝘁𝗵𝗶𝘀 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁?

The findings may help explain why biologic treatments targeting inflammation can be especially effective in some patients with chronic prurigo. The study also suggests that different inflammatory subtypes of the disease may exist, which could support more personalized treatment approaches in the future.

Full text can be found here (link also in our bio): https://pmc.ncbi.nlm.nih.gov/articles/PMC12627025/

27/05/2026

𝗦𝘂𝗺𝗺𝗲𝗿 𝘁𝗶𝗽𝘀 𝗳𝗼𝗿 𝗖𝗵𝗿𝗼𝗻𝗶𝗰 𝗣𝗿𝘂𝗿𝗶𝘁𝘂𝘀 & 𝗖𝗵𝗿𝗼𝗻𝗶𝗰 𝗣𝗿𝘂𝗿𝗶𝗴𝗼☀️🧴💧

Hot weather, sweating and sun exposure can affect sensitive skin — especially in people with chronic itch.

Some patients feel better in the summer, while others experience worsening of symptoms. There is no “one-size-fits-all” approach.
A few things that may help during hot days:

𝗞𝗲𝘆 𝗳𝗼𝗿 𝗮𝗹𝗹: 𝗨𝘀𝗲 𝘀𝘂𝗻𝘀𝗰𝗿𝗲𝗲𝗻 𝗿𝗲𝗴𝘂𝗹𝗮𝗿𝗹𝘆 𝗮𝗻𝗱 𝗽𝗿𝗲𝘃𝗲𝗻𝘁 𝘀𝘂𝗻𝗯𝘂𝗿𝗻🧴 ✨
→ ideally with a high sun protection level

𝗣𝗿𝗲𝗳𝗲𝗿 𝗹𝗶𝗴𝗵𝘁, 𝗻𝗼𝗻-𝗴𝗿𝗲𝗮𝘀𝘆 𝗲𝗺𝗼𝗹𝗹𝗶𝗲𝗻𝘁𝘀
→ special gel and lotion formulation help to moisturize dry skin in the summer

𝗪𝗲𝗮𝗿 𝗹𝗼𝗼𝘀𝗲, 𝗯𝗿𝗲𝗮𝘁𝗵𝗮𝗯𝗹𝗲 𝗰𝗹𝗼𝘁𝗵𝗶𝗻𝗴
→ for example cotton or linen fabrics

𝗗𝗼𝗻’𝘁 𝗼𝘃𝗲𝗿-𝘄𝗮𝘀𝗵 𝘁𝗵𝗲 𝘀𝗸𝗶𝗻
→ very frequent or hot showers can dry out the skin barrier

Most importantly: listen to your own skin.
Some people tolerate sun or hot temperatures very well — others do not. Finding out what helps you personally is often more important than following strict rules.

Your skin is individual, and your summer routine can be too.

Love your skin - We do🩵

26/05/2026

📣 𝐒𝐀𝐕𝐄 𝐓𝐇𝐄 𝐃𝐀𝐓𝐄 – 𝐖𝐨𝐫𝐥𝐝 𝐏𝐫𝐮𝐫𝐢𝐠𝐨 𝐃𝐚𝐲 𝟐𝟎𝟐𝟔 🌍

On 𝐉𝐮𝐧𝐞 𝟐𝟏, 𝟐𝟎𝟐𝟔, World Prurigo Day will take place — a global awareness initiative for people living with chronic prurigo/ prurigo nodularis and chronic itch. The goal of this international event is to raise awareness, advance research, and improve patient care worldwide. 🤍

Chronic prurigo is much more than “just itch.” The disease can severely affect sleep, mental health, social life, and overall quality of life. Despite this, it is still often underestimated or diagnosed too late.

World Prurigo Day brings together dermatologists, researchers, patients, and organizations from many countries around the world. More than 30 countries already participated in last year’s initiative, including Germany, France, Italy, USA, Canada, India, Brazil, Spain, Japan, and many more. 🌎

World Prurigo Day was initiated by Prof. Dr. Dr. Sonja Ständer and Prof. Dr. Matthias Augustin together with the EADV Task Force Pruritus, the International Forum for the Study of Itch (IFSI), and international prurigo organizations.

More information:
🌐 www.worldprurigoday.org

15/05/2026

🧬 Fionas Experience with Dupilumab in Prurigo Nodularis
Many patients are concerned about possible side effects or whether treatment will really help. One patient shared her personal experience with dupilumab and her journey with chronic nodular prurigo.
✨ “The itch is now about 1–2, whereas before it was a solid 8.”
According to her experience:
• Improvement started after around 2 months
• The nodules also improved after approximately 2 months
• No side effects were experienced
• Blood tests remained normal during treatment monitoring
She also described a major improvement in quality of life:
✨ “Much better and able to wear what I want.”
Before treatment, she needed to wear protective clothing in bed because scratching caused bleeding during the night. She explained that while UV phototherapy had helped temporarily in the past, the symptoms usually returned quickly. With dupilumab, the improvement persisted.
📌 This is one individual patient experience and may not reflect every patient’s response to treatment. However, sharing experiences can help reduce fear, increase awareness, and support others living with chronic prurigo.

04/05/2026

A hopeful story from Fiona (55), Edinburgh, Scotland.

Who is Fiona? Fiona is a real person who would like to share her story with us. Thank you, Fiona!

Her journey: After years of struggling with chronic prurigo, endless itching, and many unsuccessful treatments, she finally found a therapy that changed her life.

Today, she is free from itching and nodules and wants to share her journey to give others hope.

Her key message: If you are affected: don’t give up.
You are not alone, and effective treatment is possible.

29/04/2026

Long-term real-world data on Dupilumab in Prurigo Nodularis (PN)
Prurigo nodularis is a chronic, highly pruritic skin condition that significantly affects patients’ quality of life. While dupilumab is an approved treatment for moderate-to-severe PN, long-term real-world evidence has been limited—until now.
A large multicenter Italian study (DUPItaPN, n=543) evaluated effectiveness and safety in routine clinical practice over up to 104 weeks. Patients included were previously treatment-refractory and had multiple comorbidities.

✨ Key outcomes:
• Rapid and sustained itch reduction: WI-NRS decreased from 8.7 at baseline to 2.7 (week 24) and 1.7 (week 104)
• Clinically meaningful itch improvement (≥4-point WI-NRS reduction) in ~86% of patients at both 24 and 104 weeks
• Clear or almost clear skin (IGA PN-S 0/1) achieved in 62.8% at week 24 and 81.2% at week 104
• Significant improvement in quality of life: DLQI reduced from 17.4 to 2.6
• Additional benefits seen in sleep disturbance and skin pain scores

📌 Predictors & safety:
Higher baseline itch was associated with better response, while psychiatric comorbidities and prior tricyclic antidepressant use were linked to reduced response. Dupilumab showed a favorable safety profile, with only 2.9% discontinuation due to adverse events and no signals for malignancy progression or viral reactivation.

📊 Take-home message:
Dupilumab demonstrates durable efficacy and good tolerability over 2 years in real-world settings, reinforcing its role as a long-term treatment option for patients with moderate-to-severe PN—including elderly and comorbid populations.

21/04/2026

𝗖𝗵𝗿𝗼𝗻𝗶𝗰 𝗣𝗿𝘂𝗿𝗶𝘁𝘂𝘀 𝗼𝗳 𝗨𝗻𝗸𝗻𝗼𝘄𝗻 𝗢𝗿𝗶𝗴𝗶𝗻 (𝗖𝗣𝗨𝗢)

Chronic itch without a clear cause can be frustrating — and hard to treat.

🔍 𝗪𝗵𝗮𝘁 𝘄𝗲 𝗸𝗻𝗼𝘄:
• Usually caused by a mix of factors
• Immune system + nerves both play a role
• More common with aging

🩺 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀:
→ Only when other causes are ruled out

💊 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁:
No approved therapy yet, but options include creams, medications, biologics, and light therapy

💡 𝗚𝗼𝗼𝗱 𝗻𝗲𝘄𝘀:
New research is ongoing — including a clinical study on Dupilumab at University Hospital Münster

📖 https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijd.70259

17/04/2026

𝗦𝗵𝗮𝗿𝗲 𝘆𝗼𝘂𝗿 𝘀𝘁𝗼𝗿𝘆 𝗮𝗻𝗱 𝗶𝗻𝘀𝗽𝗶𝗿𝗲 𝗼𝘁𝗵𝗲𝗿𝘀 ✨

Living with chronic prurigo is not easy — but your experience might be exactly what someone else needs to hear today.

We are looking for patients who are willing to share their journey.

Tell us:
👉 What helped you?

👉 When did things start to improve?

👉 What would you want others to know?

Ready to help others? Send us a Direct Message 📩

16/04/2026

✨ 𝗖𝗵𝗿𝗼𝗻𝗶𝗰 𝗣𝗿𝘂𝗿𝗶𝗴𝗼/𝗣𝗿𝘂𝗿𝗶𝗴𝗼 𝗡𝗼𝗱𝘂𝗹𝗮𝗿𝗶𝘀: 𝗡𝗲𝘄 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗵𝗼𝗿𝗶𝘇𝗼𝗻?

Treating PN has long been challenging — but new biologics are changing the game.

🔬 A recent clinical trial tested 𝗩𝗶𝘅𝗮𝗿𝗲𝗹𝗶𝗺𝗮𝗯 in 190 patients worldwide.

👉 𝙒𝙝𝙖𝙩 𝙞𝙨 𝙞𝙩?
A targeted antibody that blocks key pathways involved in itch, inflammation, and skin thickening

⚡ 𝗞𝗲𝘆 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀:
• Fast itch relief – improvement after just 2 weeks
• Stronger effect with higher doses
• Significant itch reduction vs. placebo after 16 weeks
• Skin lesions improved across all groups
• Well tolerated – mostly mild side effects

💡 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆:
Vixarelimab shows rapid and lasting improvements in both itch and skin symptoms — with good safety over time.

📖 Jama Dermatology (2026)

08/04/2026

👉 You asked — we answered.

Your most common questions about chronic prurigo, based on science and real experience.
💬 What else do you want to know?

Adresse

Münster

Webseite

http://www.skinhealthcampus.org/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Prurigo Nodularis League erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Die Universität Kontaktieren

Nachricht an Prurigo Nodularis League senden:

Verknüpfungen

Wollen Sie Ihr Universität zum Top-Universität in Münster machen?